Back to Search
Start Over
Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis.
- Source :
-
Archivos espanoles de urologia [Arch Esp Urol] 2022 May 28; Vol. 75 (4), pp. 354-360. - Publication Year :
- 2022
-
Abstract
- Objectives: The aim was to study the efficacy and tolerance in patients with haemorrhagic radiation-induced cystitis (HRC) treated with hyperbaric oxygen therapy (HOT) and analyze which factors were related to the response to the treatment.<br />Material and Methods: We performed a retrospective cohort study of patients treated with HOT for HRC symptoms in a provincial referral centre from 2010 to 2020. We evaluated clinical response to treatment, number of hospitalizations due to HRC and subjective response using the PGI-I questionnaire.<br />Results: We treated 52 patients, with a median of 30 sessions, during 6 months and 40 months (6-68 months) of follow-up. 69.2%of patients responded completely and 21,2% partially. The 53.2% of patients improved before the first 10 sessions. Reduction of hospitalizations/per year due to haematuria from 2.8 to 1.1 (p=0,001). The 73,5% of patients stated that they were "very much better" or "much better" after treatment. During the follow-up, 15.4% of patients had recurrence of HRC. 9.6% of the patients required salvage cystectomy. The patients with a highest RTOG-EORTC scale had more risk to still with symptoms (OR 3.01 (IC95 1.48 - 6.16). All patients were able to complete the proposed treatment plan with good tolerance to HOT.<br />Conclusions: These results show the clinical benefit of HOT in the treatment of HRC, with a reduction of the number of hospitalizations and a subjective improvement.
Details
- Language :
- English
- ISSN :
- 0004-0614
- Volume :
- 75
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Archivos espanoles de urologia
- Publication Type :
- Academic Journal
- Accession number :
- 35818916
- Full Text :
- https://doi.org/10.56434/j.arch.esp.urol.20227504.50